Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Melatonin for Uveal Melanoma: A Randomized Open Phase III Study

NCT05502900 is registered in ClinicalTrials.gov with Gustav Stalhammar as lead sponsor.

NCT NCT05502900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05502900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Melatonin for Uveal Melanoma: A Randomized Open Phase III Study
Lead sponsor
Gustav Stalhammar
Phase
Phase 3
Overall status
Recruiting
Start date
October 2, 2022
Completion date
January 1, 2031
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

eye cancer, intraocular melanoma, uveal melanoma, uveal melanoma, posterior, medium/large size